<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVE: The aim of this study was to describe the use and efficacy of low-dose (≤2 mg) droperidol for the treatment of primary <z:hpo ids='HP_0002315'>headaches</z:hpo> (ie, <z:hpo ids='HP_0002076'>migraine</z:hpo>, cluster, tension-type <z:hpo ids='HP_0002315'>headache</z:hpo> and <z:e sem="disease" ids="C1565172" disease_type="Disease or Syndrome" abbrv="">trigeminal autonomic cephalalgias</z:e>, and other primary <z:hpo ids='HP_0002315'>headaches</z:hpo>) in the emergency department (ED) </plain></SENT>
<SENT sid="1" pm="."><plain>METHODS: A report was generated from a pharmacy database to identify <z:hpo ids='HP_0000001'>all</z:hpo> adult patients who received low-dose droperidol in the ED over a 7-month period; a subsequent retrospective chart review was conducted </plain></SENT>
<SENT sid="2" pm="."><plain>Low-dose droperidol was defined as a cumulative dose of ���2 mg </plain></SENT>
<SENT sid="3" pm="."><plain>Patients who received droperidol for any other reason than the treatment of a <z:hpo ids='HP_0002315'>headache</z:hpo> were excluded </plain></SENT>
<SENT sid="4" pm="."><plain>Data were analyzed descriptively </plain></SENT>
<SENT sid="5" pm="."><plain>RESULTS: Seventy-three cases in which droperidol was administered for the treatment of a <z:hpo ids='HP_0002315'>headache</z:hpo> were identified over the 7-month period </plain></SENT>
<SENT sid="6" pm="."><plain>Most doses (92%) administered were 1.25 mg or less </plain></SENT>
<SENT sid="7" pm="."><plain>Fifty-three patients (73%) had complete resolution or significant improvement of <z:hpo ids='HP_0002315'>headache</z:hpo> symptoms as subjectively or objectively (eg, numerical pain scale) documented by the treating physician </plain></SENT>
<SENT sid="8" pm="."><plain>Eight patients (11%) had minimal improvement in their <z:hpo ids='HP_0002315'>headaches</z:hpo> symptoms; 12 patients (16%) received no relief after the administration of droperidol </plain></SENT>
<SENT sid="9" pm="."><plain>The average time to discharge from the ED was 94.8 ± 67.2 minutes </plain></SENT>
<SENT sid="10" pm="."><plain>No <z:hpo ids='HP_0011675'>cardiac arrhythmias</z:hpo> were noted </plain></SENT>
<SENT sid="11" pm="."><plain>Other adverse events included 2 cases of extrapyramidal side effects; one patient reported <z:hpo ids='HP_0000711'>restlessness</z:hpo>/anxiousness and the other patient had <z:hpo ids='HP_0001332'>dystonia</z:hpo> </plain></SENT>
<SENT sid="12" pm="."><plain>CONCLUSION: The administration of low-dose (≤2 mg) droperidol may be safe and effective for the treatment of primary <z:hpo ids='HP_0002315'>headaches</z:hpo> in the ED </plain></SENT>
</text></document>